Natera, Inc. (NASDAQ:NTRA)
| Market Cap | 47.11B+95.2% |
| Revenue (ttm) | 2.71B+37.8% |
| Net Income | -192.35M+24.0% |
| EPS | -1.36+28.8% |
| Shares Out | 143.22M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 797,995 |
| Open | 330.18 |
| Previous Close | 326.14 |
| Day's Range | 324.45 - 330.18 |
| 52-Week Range | 157.43 - 343.18 |
| Beta | 1.53 |
| Analysts | Buy |
| Price Target | 335.07(+1.87%) |
| Earnings Date | Nov 5, 2026 |
About NTRA
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$NTRA stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in NTRA holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by NTRA's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
NTRA Estimated quarterly lobbying spending
Source: U.S. Senate LDA
NTRA Revenue by Segment or Geography
| Segment | Revenue | % of All |
|---|---|---|
| Insurance carriers | $705.09M | 93.67% |
| Laboratory partners | $37.74M | 5.01% |
| Patients | $9.92M | 1.32% |
As of: Q2 2026 (Jun 30, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New NTRA patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to NTRA from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in NTRA
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $1.16B |
| VBVanguard Morningstar Small-Cap ETF | $837.28M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $484.38M |
| VXFVanguard Extended Market ETF | $441.68M |
| IBBiShares Biotechnology ETF | $343.72M |
| IWPiShares Russell Mid-Cap Growth ETF | $254.37M |
Estimated from each fund’s disclosed top holdings × AUM
NTRA Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from NTRA’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score